Ernest H S Choy

Summary

Affiliation: King's College London
Country: UK

Publications

  1. ncbi Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial
    E H S Choy
    Guy s, King s, and St Thomas School of Medicine, King s College, London, UK
    Arthritis Rheum 46:3143-50. 2002
  2. ncbi Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis
    E Choy
    Academic Department of Rheumatology, GKT School of Medicine, King's College Hospital, London, UK
    Ann Rheum Dis 62:ii68-9. 2003
  3. ncbi A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal
    E H S Choy
    Sir Alfred Baring Clinical Trials Unit, Academic Department of Rheumatology, GKT School of Medicine, King s College London, UK
    Rheumatology (Oxford) 44:1414-21. 2005
  4. ncbi Patients' experiences of living with and receiving treatment for fibromyalgia syndrome: a qualitative study
    Heidi K Lempp
    Academic Rheumatology NIHR Guy s and St Thomas Foundation Trust Biomedical Research Centre, King s College London, Weston Education Centre, 10, Cutcombe Road, London, SE5 9RJ, UK
    BMC Musculoskelet Disord 10:124. 2009
  5. ncbi A patient survey of the impact of fibromyalgia and the journey to diagnosis
    Ernest Choy
    Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department of Rheumatology, King s College London, UK
    BMC Health Serv Res 10:102. 2010
  6. ncbi Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT
    Dafna D Gladman
    University of Toronto, 399 Bathurst Street, Room 1E 410B, Toronto, Ontario M5T 2S8, Canada
    Arthritis Res Ther 12:R113. 2010
  7. ncbi Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study
    Antonio Naranjo
    Hospital de Gran Canaria Dr, Negrin, University of Las Palmas de Gran Canaria, Barranco de la Ballena s n 35011, Spain
    Arthritis Res Ther 10:R30. 2008
  8. ncbi Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis
    Ernest Choy
    Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department of Rheumatology, 2nd Floor, Weston Education Centre, GKT School of Medicine, King s College Hospital, Cutcombe Road, London SE5 9PJ, UK
    Cytokine 28:158-61. 2004
  9. ncbi Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective
    Ernest Choy
    King s Musculoskeletal Clinical Trials Unit, Academic Department of Rheumatology, King s College London, London, UK
    Curr Med Res Opin 26:965-75. 2010
  10. ncbi Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome
    Ernest H Choy
    Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department Rheumatology, Weston Education Centre, King s College London, Cutcombe Road, London, SE5 9RJ UK
    J Rheumatol 36:2330-4. 2009

Collaborators

Detail Information

Publications23

  1. ncbi Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial
    E H S Choy
    Guy s, King s, and St Thomas School of Medicine, King s College, London, UK
    Arthritis Rheum 46:3143-50. 2002
    ..To investigate the safety and efficacy of MRA, a recombinant human anti-interleukin-6 (anti-IL-6) receptor monoclonal antibody of the IgG1 subclass that inhibits the function of IL-6, in patients with established rheumatoid arthritis (RA)...
  2. ncbi Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis
    E Choy
    Academic Department of Rheumatology, GKT School of Medicine, King's College Hospital, London, UK
    Ann Rheum Dis 62:ii68-9. 2003
  3. ncbi A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal
    E H S Choy
    Sir Alfred Baring Clinical Trials Unit, Academic Department of Rheumatology, GKT School of Medicine, King s College London, UK
    Rheumatology (Oxford) 44:1414-21. 2005
    ..We undertook a systematic review of combination DMARD therapy for RA and carried out a meta-analysis to evaluate the evidence for efficacy and toxicity...
  4. ncbi Patients' experiences of living with and receiving treatment for fibromyalgia syndrome: a qualitative study
    Heidi K Lempp
    Academic Rheumatology NIHR Guy s and St Thomas Foundation Trust Biomedical Research Centre, King s College London, Weston Education Centre, 10, Cutcombe Road, London, SE5 9RJ, UK
    BMC Musculoskelet Disord 10:124. 2009
    ..The aetiology is multi-dimensional, involving somatic, psychological and social factors. Patients' views were obtained to understand their experience of living with this long-term condition, using qualitative interviews...
  5. ncbi A patient survey of the impact of fibromyalgia and the journey to diagnosis
    Ernest Choy
    Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department of Rheumatology, King s College London, UK
    BMC Health Serv Res 10:102. 2010
    ..This survey examined the patient journey to having their condition diagnosed and studied the impact of the condition on their life...
  6. ncbi Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT
    Dafna D Gladman
    University of Toronto, 399 Bathurst Street, Room 1E 410B, Toronto, Ontario M5T 2S8, Canada
    Arthritis Res Ther 12:R113. 2010
    ..To identify independent predictors of radiographic progression in psoriatic arthritis (PsA) for patients treated with adalimumab or placebo in the Adalimumab Effectiveness in PsA Trial (ADEPT)...
  7. ncbi Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study
    Antonio Naranjo
    Hospital de Gran Canaria Dr, Negrin, University of Las Palmas de Gran Canaria, Barranco de la Ballena s n 35011, Spain
    Arthritis Res Ther 10:R30. 2008
    ....
  8. ncbi Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis
    Ernest Choy
    Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department of Rheumatology, 2nd Floor, Weston Education Centre, GKT School of Medicine, King s College Hospital, Cutcombe Road, London SE5 9PJ, UK
    Cytokine 28:158-61. 2004
    ..In the UK, they are approved for the treatment of rheumatoid arthritis in patients with active disease who have failed at least two disease modifying anti-rheumatic drugs...
  9. ncbi Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective
    Ernest Choy
    King s Musculoskeletal Clinical Trials Unit, Academic Department of Rheumatology, King s College London, London, UK
    Curr Med Res Opin 26:965-75. 2010
    ..Fibromyalgia is a chronic condition associated with widespread pain, sleep disturbance and disability. Disease related costs are high and effective treatment options few...
  10. ncbi Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome
    Ernest H Choy
    Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department Rheumatology, Weston Education Centre, King s College London, Cutcombe Road, London, SE5 9RJ UK
    J Rheumatol 36:2330-4. 2009
    ..This aligns with the key objective of the Outcome Measures in Rheumatology (OMERACT) initiative to improve outcome measurement through a data driven, interactive consensus process...
  11. ncbi Key symptom domains to be assessed in fibromyalgia (outcome measures in rheumatoid arthritis clinical trials)
    Ernest H Choy
    Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department Rheumatology, Weston Education Centre, King s College London, Cutcombe Road, London, UK
    Rheum Dis Clin North Am 35:329-37. 2009
    ..This aligns with the key objective of the Outcome Measures in Rheumatoid Arthritis Clinical Trials initiative to improve outcome measurement in rheumatic diseases through a data-driven interactive consensus process...
  12. ncbi Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis
    E H Choy
    King s College Hospital, London, UK
    Clin Exp Rheumatol 27:510-8. 2009
    ..This review will highlight abatacept as an important treatment option in the therapeutic repertoire for RA that selectively modulates T-cell co-stimulation...
  13. ncbi Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials
    Ernest H S Choy
    Department of Rheumatology, Weston Education Centre, King s College London, London SE5 9RJ, UK
    Clin Rheumatol 28:1035-44. 2009
    ..In addition, postmarketing surveillance continues for adverse events reported with duloxetine in fibromyalgia, as in other indications...
  14. ncbi RADIATE: more treatment options for patients with an inadequate response to tumor necrosis factor antagonists
    Ernest Choy
    Academic Department of Rheumatology, King s College London, London, UK
    Nat Clin Pract Rheumatol 5:66-7. 2009
    ..Randomized controlled trials and the study of biomarkers are needed to help clinicians select the most suitable of these options for their patients...
  15. ncbi Inhibiting interleukin-6 in rheumatoid arthritis
    Ernest Choy
    Academic Department of Rheumatology, 2nd Floor, Weston Education Centre, King s College London, Cutcombe Road, London, SE5 9PJ, United Kingdom
    Curr Rheumatol Rep 10:413-7. 2008
    ..Clinical trials of tocilizumab, a humanized anti-IL-6 receptor monoclonal antibody that blocks IL-6 signaling, have demonstrated therapeutic benefit. It heralds a new era of anticytokine therapy in rheumatoid arthritis...
  16. ncbi Clinical experience with inhibition of interleukin-6
    Ernest Choy
    Sir Alfred Baring Garrod Clinical Trials Unit, Department of Rheumatology, GKT School of Medicine, 2nd Floor, Weston Education Centre, King s College London, Cutcombe Road, London, UK SE5 9PJ
    Rheum Dis Clin North Am 30:405-15, viii. 2004
    ..Interleukin-6 (IL-6) is a key mediator of inflammation in RA. Inhibition of IL-6 reduces synovitis and improves symptoms. Therapies targeting IL-6 are promising new treatments for RA...
  17. ncbi Development and validation of a patient-based disease activity score in rheumatoid arthritis that can be used in clinical trials and routine practice
    Ernest H Choy
    Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department of Rheumatology, King s College London, London, UK
    Arthritis Rheum 59:192-9. 2008
    ..We developed and validated a patient-based disease activity score (PDAS) as an alternative assessment...
  18. ncbi T cells in psoriatic arthritis
    Ernest Choy
    Academic Department of Rheumatology, King s College London, Weston Education Center, Cutcombe Road, London, SE5 9PJ, UK
    Curr Rheumatol Rep 9:437-41. 2007
    ..The therapeutic benefit of anti-T-cell agents further supports an important pathogenic role for T cells in persistent synovial inflammation and joint damage in psoriatic arthritis...
  19. ncbi Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis
    E H S Choy
    Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department of Rheumatology, King s College School of Medicine, Weston Education Centre, Cutcombe Road, London SE5 9RJ, UK
    Ann Rheum Dis 67:656-63. 2008
    ..As the relative benefits of combining two DMARDs, one DMARD with glucocorticoids and two DMARDs with glucocorticoids are uncertain we defined them in a factorial trial...
  20. ncbi Oral toleragens in rheumatoid arthritis
    E H Choy
    Department of Rheumatology, Guy s, King s and St Thomas Hospitals School of Medicine, King s College Hospital, East Dulwich Grove, London, SE22 8PT, UK
    Curr Opin Investig Drugs 1:58-62. 2000
    ..This review examines the scientific basis of oral tolerance, discusses the apparent discrepancy in clinical trial results and looks at the future prospect...
  21. ncbi Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica
    Andrew Hutchings
    London School of Hygiene and Tropical Medicine, London, UK
    Arthritis Rheum 57:803-9. 2007
    ....
  22. ncbi Systematic review of discriminating power of outcome measures used in clinical trials of fibromyalgia
    Serena F Carville
    Sir Alfred Baring Garrod Clinical Trials Unit, Department of Academic Rheumatology, King s College London, London, UK
    J Rheumatol 35:2094-105. 2008
    ..We investigated those outcome measures and instruments in association with the OMERACT (Outcome measures in Rheumatoid Arthritis Clinical Trials) FM Workshop initiative to define core outcome measures that should be used to assess FM...
  23. ncbi Clinical and radiological features of rheumatoid arthritis in British black Africans
    Vinod Ravindran
    Department of Clinical and Academic Rheumatology, King s College Hospital, Denmark Hill, London, UK
    Clin Rheumatol 27:97-100. 2008
    ..A large prospective study is required to confirm the findings of this study and to establish the factors which might be accountable for any differences in the expression of rheumatoid arthritis in this ethnic group...